RxDoctor Payments Data

Laybon Jones, MD

Cardiovascular Disease · Vallejo, CANPI 1205972296

Payments from drug & device makers

$14,032in general payments, 2019–2025

Across 194 payments — averaging $72.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$9K
  • Cathworks, Inc.$1K
  • Abiomed$1K
  • Abbott$829
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$671
  • Johnson & Johnson$191
  • plus $1K from 12 others

What the payments were for

  • Consulting fees$1,0007%
  • Food & beverage$13,03293%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,032 in reported general payments places this provider in the 75th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$172,371
Medicare patients
587
Services billed
1,956

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban204$215,981
EntrestoSacubitril/Valsartan140$137,268
XareltoRivaroxaban87$98,324
Ranolazine ErRanolazine18$4,203
Nebivolol Hcl23$2,503
Carvedilol236$1,641
Atorvastatin Calcium126$1,272
Amlodipine Besylate270$1,136
Amiodarone Hcl33$819
Metoprolol Succinate49$746
Losartan Potassium74$628
Metoprolol Tartrate69$592
Chlorthalidone35$566
Potassium Chloride27$557
Digoxin13$341

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$107$215,981204 claims
NovartisEntresto$118$137,268140 claims
Johnson & JohnsonXarelto$191$98,32487 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Vallejo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →